Today, most people don’t receive medical interventions until they are symptomatic. However, the application of AI in medical imaging is increasingly supporting early detection of lung cancer, heart disease, airway disease, osteoporosis and more. As we look to the near future, the opportunistic or incidental detection of disease is at the heart of population health.
We are leveraging the tremendous amount of information in a chest CT to provide improved accuracy and quantification of multiple conditions in pulmonary, cardiac, and skeletal health. Opportunitistic screening of asymptomatic patients can lead to earlier detection, improved treatment options, and better outcomes.
The newest innovation from ClearReadTM CT will transform cardiac health through early, incidental, and accurate detection of biomarkers without extra procedures or time-consuming measurements. Schedule a demo by filling out the form to learn more about the Next Big Thing from Riverain Technologies.
Attending RSNA 2024? Visit our booth #4523 to see the newest innovations. Subscribe to our RSNA updates to learn more about the show and ClearRead CT.